Have questions, feedback, or need further support? We’d love to hear from you! We're always working to improve our high-quality products, and your experiences, concerns, and suggestions are important to us. Thank you for helping us grow!
Please fill out this form with your contact information and one of our representatives will reach out to you using the information provided.
Information provided by Teleflex Incorporated is for general informational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Teleflex Incorporated is not authorised to provide medical advice or treatment to patients. If you have any questions about your medical condition and or medical device, consult your physician. If you experience any adverse events or side effects related to the UroLift System, consult your physician immediately. You can also report your experience by contacting us at uroliftsupport.emea@teleflex.com.
Teleflex Medical Europe Ltd
IDA Business and Technology Park
Dublin Road, Athlone
Co Westmeath
Ireland
Phone: +353 (0) 9 06 46 08 00
Fax: +353 (0) 14 37 07 73
Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate and /or the inability to control the urge (Roehrborn, J Urology 2013). Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Speak with your doctor to determine if you may be a candidate.
Teleflex, the Teleflex logo, UroLift, the UroLift logo, BPH Advisor, MyBPH Report, and UroLift ATC are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the US and/or other countries.
IDA Business and Technology Park
Dublin Road, Athlone
Co Westmeath
© 2025 Teleflex Inc. All rights reserved. | Terms of Use | Internet Privacy Policy | Patient Safety | Imprint | Compliance
MCI-2022-0109